Date: 30 Jun 2017
Story by AASLD.
“Liver disease continues to be a critical healthcare issue in the United States and internationally. Despite recent strides and successes in the treatment of many liver diseases, AASLD Foundation understands there is still much work to be done and more funding must be made available to those interested in hepatology.” - Bruce R. Bacon, MD, FAASLD, AASLD Foundation Chair.Read More
Date: 26 Jun 2017
"When you combine the fact that the natural history of the disease is unclear; it's difficulty to diagnose, treat and stage it; and there's no FDA-approved medicine, it becomes a huge issue." - Dr. Jaideep Behari, associate professor of medicine at the University of Pittsburgh and director of Fatty Liver Clinic.Read More
Date: 19 Jun 2017
"According to researchers, first-degree relatives of patients with nonalcoholic fatty liver disease and cirrhosis have a 12-times higher risk for developing advanced fibrosis compared with first-degree relatives without NAFLD."Read More
Date: 13 Jun 2017
Research and Markets has announced the addition of the "Non-Alcoholic Fatty Liver Disease (NAFLD) Forecast in 11 Major Markets 2017-2027" report to their offering.Read More
Date: 01 Jun 2017
“Specifically, EMA says the diseases pose a significant challenge for drugmakers to study, as all three have a long progression and symptoms that are either unspecific or non-predictive of long-term outcomes."Read More
Date: 31 May 2017
Watch this video to hear the full message.
Carlos Moedas, European Commissioner for Research, Science and Innovation, stressed the "need to scale up efforts in research and innovation [to] develop simple, cost-effective and non-invasive tests" that will allow to "improve guidance to member states on primary care and better management".Read More